Genmab enters agreement on cancer biomarker

A supply agreement will give the Danish firm access to US-based biotech company Imaginab’s oncology imaging technology in future clinical trials.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by christian bundgaard, translated by daniel pedersen

Danish biotech firm Genmab has struck a supply deal with Imaginab, a US-based biotech firm that is developing imaging technology for cancer treatments, the latter firm has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms